コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 y end point was to compare overall survival (Kaplan-Meier analysis).
2 were 6.5% and 6.7%, respectively (unadjusted Kaplan-Meier analysis).
3 84% for pre-LT and 93% for post-LT patients (Kaplan-Meier analysis).
4 corneal thickness (CCT), and graft survival (Kaplan-Meier analysis).
5 d 71% at 1, 3, and 5 years, respectively, by Kaplan Meier analysis.
6 Survival was analyzed by Kaplan-Meier analysis.
7 al of bladder cancer patients as revealed by Kaplan-Meier analysis.
8 ation of reduced recurrence-free survival by Kaplan-Meier analysis.
9 999 copies/mL) for 6, 9, or 12 months, using Kaplan-Meier analysis.
10 tive risk (lambda) and cumulative risk using Kaplan-Meier analysis.
11 number of photographs taken was evaluated by Kaplan-Meier analysis.
12 stable microsatellites P = .0415), based on Kaplan-Meier analysis.
13 rates divided by incidence, as estimated by Kaplan-Meier analysis.
14 tional hazards regression model analysis and Kaplan-Meier analysis.
15 rvival (PFS) and overall survival (OS) using Kaplan-Meier analysis.
16 ion-free survival and overall survival using Kaplan-Meier analysis.
17 Survival was assessed using Kaplan-Meier analysis.
18 us immunosuppressant use was estimated using Kaplan-Meier analysis.
19 ar cumulative percentage of MAE was 12.5% by Kaplan-Meier analysis.
20 cause-specific survival (CSS), P = 0.012] by Kaplan-Meier analysis.
21 al hazards modeling and were evaluated using Kaplan-Meier analysis.
22 tuarial overall survival was calculated with Kaplan-Meier analysis.
23 Long-term survival was evaluated by Kaplan-Meier analysis.
24 m the first TACE session was calculated with Kaplan-Meier analysis.
25 cumulative incidence of PD was calculated by Kaplan-Meier analysis.
26 tients was assessed using Cox regression and Kaplan-Meier analysis.
27 dney transplants at the same center by using Kaplan-Meier analysis.
28 tients was assessed using Cox regression and Kaplan-Meier analysis.
29 Survival was determined by Kaplan-Meier analysis.
30 atus, and time to recurrence on the basis of Kaplan-Meier analysis.
31 elopment of metastases was analyzed by using Kaplan-Meier analysis.
32 n 1 year of transplantation were assessed by Kaplan-Meier analysis.
33 ranslocation in human PNI was analyzed using Kaplan-Meier analysis.
34 Survival was determined by Kaplan-Meier analysis.
35 and HIV-1-free survival were assessed using Kaplan-Meier analysis.
36 g-donor KTA or with a LKTx was obtained from Kaplan-Meier analysis.
37 ecreased patient and graft survival rates by Kaplan-Meier analysis.
38 which was significant in both chi-square and Kaplan-Meier analysis.
39 (+/- distant metastasis) were calculated by Kaplan-Meier analysis.
40 n rank-sum tests, the Fisher exact test, and Kaplan-Meier analysis.
41 ative risk of treatment failure by day 28 by Kaplan-Meier analysis.
42 associated genetic variants were assessed by Kaplan-Meier analysis.
43 he recurrence-free curve was estimated using Kaplan-Meier analysis.
44 d probability of rebound and resistance with Kaplan-Meier analysis.
45 splantation graft survival was assessed with Kaplan-Meier analysis.
46 oth univariate and multivariate analysis and Kaplan-Meier analysis.
47 A, NRP-1, FOXO 3a and MelCAM were studied by Kaplan-Meier analysis.
48 Device longevity was estimated using Kaplan-Meier analysis.
49 The patency was evaluated by Kaplan-Meier analysis.
50 th graft survival was also explored by using Kaplan-Meier analysis.
52 e who did not have angiography, according to Kaplan-Meier analysis (281/3085 [12.8%] vs 480/4158 [16.
55 median follow-up of 5.2 (3.6, 6.9) years on Kaplan-Meier analysis, a significant nonlinear associati
58 overall survival discrimination, with use of Kaplan Meier analysis and a univariate Cox proportional
59 nt recipients 61 years of age or older using Kaplan- Meier analysis and Cox proportional hazard model
60 ters and survival time was assessed by using Kaplan-Meier analysis and a Cox proportional hazards mod
61 to cancer in the two groups was compared by Kaplan-Meier analysis and a Cox proportional-hazards mod
63 se Neuroimaging Initiative were evaluated by Kaplan-Meier analysis and analyses of variance and covar
64 sed mortality within 90 days of operation by Kaplan-Meier analysis and assessed the role of patient a
66 ated the probability of recanalisation using Kaplan-Meier analysis and conducted multivariate analysi
67 tality were analyzed by NYHA IV status using Kaplan-Meier analysis and Cox proportional hazard models
68 s and survival outcomes were investigated by Kaplan-Meier analysis and Cox proportional hazard models
70 Recurrence and survival were analyzed using Kaplan-Meier analysis and Cox proportional hazards model
76 idence of clinical outcome was determined by Kaplan-Meier analysis and Cox regression was used to eva
83 ere complete success rates at 24 months with Kaplan-Meier analysis and incidence of adverse events.
91 Bi- and multivariable logistic regression, Kaplan-Meier analysis, and Cox proportional hazards mode
93 tical methods included analysis of variance, Kaplan-Meier analysis, and Mantel-Cox proportional hazar
94 mption of continuous smoking was assessed by Kaplan-Meier analysis, and risk differences between grou
98 success of second glaucoma drainage devices (Kaplan-Meier analysis) at 1 year, 2 years, and 3 years w
102 respect to HNSCC staging were compared using Kaplan-Meier analysis, Cox proportional hazards regressi
128 tumor location demonstrated superior BCSS on Kaplan-Meier analysis for both local stage (node-negativ
138 Successful trabeculectomies, determined by Kaplan-Meier analysis, in which patients have intraocula
146 gher colorectal cancer-specific mortality in Kaplan-Meier analysis (log-rank test, P < 0.0001), univa
147 iac risk factors and CMR were significant in Kaplan-Meier analysis (log-rank test, p = 0.0006 and p <
148 icantly with poor survival prognosis using a Kaplan-Meier analysis (log-rank test, P=5 x 10(-4)), sug
151 ariate adjusted outcomes were assessed using Kaplan-Meier analysis, multivariate cox regression, mult
154 Three prediction methods were compared, Kaplan-Meier analysis of all possible subsets, recursive
159 ere randomized into eight treatment arms for Kaplan-Meier analysis of defined survival end-point (3.0
173 up vs 43.3% (565/1304) in the placebo group, Kaplan-Meier analysis of time to death by 1 year, P = .7
179 ssociated with survival from presentation in Kaplan-Meier analysis (p < 0.01), and loss of 1p36 and 1
182 antly lower overall mortality, determined by Kaplan-Meier analysis (P=.0047), univariate Cox regressi
195 nipulation and no AI at the time of implant, Kaplan-Meier analysis revealed that freedom from greater
241 Using unadjusted and adjusted Cox models and Kaplan-Meier analysis, there was no significant differen
244 learance kinetics, measured every 6 h, and a Kaplan-Meier analysis to compare parasite clearance kine
248 The associations were further delineated by Kaplan-Meier analysis using publicly available mRNA expr
253 Median renal survival from diagnosis by Kaplan-Meier analysis was 5.4 years, and median estimate
270 tory abilities of inflammation-based scores; Kaplan-Meier analysis was performed to plot the survival
274 as in patients with limited life expectancy, Kaplan-Meier analysis was repeated including only patien
277 mplications and of need for reoperation, and Kaplan-Meier analysis was used to assess graft survival
288 At 1 year, the rate of death from any cause (Kaplan-Meier analysis) was 30.7% with TAVI, as compared
289 l success at the last follow-up according to Kaplan-Meier analysis were 100% and 94.4% in bevacizumab
290 Five-year patient and graft survivals by Kaplan-Meier analysis were significantly lower for type
293 [CI], 0.71 to 1.15; P=0.41) and at 2 years (Kaplan-Meier analysis) were 33.9% in the TAVR group and
294 he 1-, 12-, and 24-month mortality rates (by Kaplan-Meier analysis) were 4.5%, 15.8%, and 15.8%, resp
295 CD20+ cells/hpf had worse graft survival in Kaplan-Meier analysis with a hazard ratio 4.56 (CI 1.07-
297 Overall survival (OS) was compared using Kaplan-Meier analysis with log-rank tests and multivaria
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。